Edwards Lifesciences (NYSE:EW) is ending its planned acquisition of JenaValve. The company is redirecting the capital that ...
Several medical societies supported extending Medicare coverage for TAVR to patients with asymptomatic aortic stenosis, but ...
Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...
Edwards pushes CMS to expand Medicare TAVR coverage to asymptomatic patients, sparking controversy among physicians over ...
A recent federal district court decision in FTC v. Edwards Lifesciences adds another win to U.S. enforcers’ efforts to apply traditional ...
The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...
Edwards Lifesciences Corp. faced a legal loss early this month that forced it to call off its $945 million acquisition of ...
Medical Device Network on MSN
Edwards’ JenaValve acquisition nixed as FTC injunction approved by court
The FTC sued Edwards in August 2025, citing competition concerns in the nascent TAVR-AR market amid a potential deal for JenaValve.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results